Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing ...

Contract manufacturers have carved out a lucrative niche within the biopharma industry, and the value of their collective capacity and production agility was on full display during the COVID-19 ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if ...

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "AI in Pharma Manufacturing Market, till 2040: Distribution by Type of Offering, Mode of Deployment, Type of AI Solution, Type of Technology, Application ...

Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 square-foot manufacturing facility Seagen was building north of Seattle near ...

March 3 (Reuters) - Pfizer (PFE.N), opens new tab CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other ...

President Donald Trump announced a deal with Pfizer (PFE) on Tuesday that includes steep drug price cuts and a $70 billion investment in domestic manufacturing facilities. Speaking at the White House, ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research ...